Following on from information provided to NICE by the company in December 2021, the appraisal of Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1142 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 December 2022 | Discontinued. Following on from information provided to NICE by the company in December 2021, the appraisal of Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 24 December 2021 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of moxetumomab pasudotox for treating hairy-cell leukaemia. For information, the company has advised that it is no longer pursuing a Marketing Authorisation Application from the European Medicines Agency (EMA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 18 March 2020 - 08 April 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3 |
| 25 July 2018 - 15 August 2018 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2 |
| 18 January 2018 - 08 February 2018 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1 |
For further information on our processes and methods, please see our CHTE processes and methods manual